Literature DB >> 21047723

IL-32 is increased along with tryptase in lesional psoriatic skin and is up-regulated by substance P in human mast cells.

Duraisamy Kempuraj, Pio Conti, Magdalini Vasiadi, Konstantinos-Dionysios Alysandratos, Michael Tagen, Dimitrios Kalogeromitros, Taxiarchis Kourelis, Stamatios Gregoriou, Michael Makris, Nikolaos G Stavrianeas, Theoharis C Theoharides.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21047723      PMCID： PMC3273318          DOI： 10.1684/ejd.2010.1110

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN： 1167-1122            Impact factor:   3.328


× No keyword cloud information.
  6 in total

Review 1.  Psoriasis.

Authors:  Frank O Nestle; Daniel H Kaplan; Jonathan Barker
Journal:  N Engl J Med       Date:  2009-07-30       Impact factor: 91.245

2.  Study of substance P and its receptor neurokinin-1 in psoriasis and their relation to chronic stress and pruritus.

Authors:  Charlotta Remröd; Solbritt Lonne-Rahm; Klas Nordlind
Journal:  Arch Dermatol Res       Date:  2007-03-17       Impact factor: 3.017

3.  IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis.

Authors:  Norbert Meyer; Maya Zimmermann; Simone Bürgler; Claudio Bassin; Stefan Woehrl; Katharina Moritz; Claudio Rhyner; Philippe Indermitte; Peter Schmid-Grendelmeier; Mübeccel Akdis; Günter Menz; Cezmi A Akdis
Journal:  J Allergy Clin Immunol       Date:  2010-03-15       Impact factor: 10.793

4.  IL-32, a proinflammatory cytokine in rheumatoid arthritis.

Authors:  Leo A B Joosten; Mihai G Netea; Soo-Hyun Kim; Do-Young Yoon; Birgitte Oppers-Walgreen; Timothy R D Radstake; Pilar Barrera; Fons A J van de Loo; Charles A Dinarello; Wim B van den Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

Review 5.  Is there a role for mast cells in psoriasis?

Authors:  Ilkka T Harvima; Gunnar Nilsson; Mireille-Maria Suttle; Anita Naukkarinen
Journal:  Arch Dermatol Res       Date:  2008-08-22       Impact factor: 3.017

6.  IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin.

Authors:  Theoharis C Theoharides; Bodi Zhang; Duraisamy Kempuraj; Michael Tagen; Magdalini Vasiadi; Asimenia Angelidou; Konstantinos-Dionysios Alysandratos; Dimitris Kalogeromitros; Shahrzad Asadi; Nikolaos Stavrianeas; Erika Peterson; Susan Leeman; Pio Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205
  6 in total
  13 in total

1.  IL-32 promotes angiogenesis.

Authors:  Claudia A Nold-Petry; Ina Rudloff; Yvonne Baumer; Menotti Ruvo; Daniela Marasco; Paolo Botti; Laszlo Farkas; Steven X Cho; Jarod A Zepp; Tania Azam; Hannah Dinkel; Brent E Palmer; William A Boisvert; Carlyne D Cool; Laima Taraseviciene-Stewart; Bas Heinhuis; Leo A B Joosten; Charles A Dinarello; Norbert F Voelkel; Marcel F Nold
Journal:  J Immunol       Date:  2013-12-11       Impact factor: 5.422

Review 2.  Potential therapeutic use of IL-37: a key suppressor of innate immunity and allergic immune responses mediated by mast cells.

Authors:  Pio Conti; Francesco Carinci; Gianfranco Lessiani; Enrico Spinas; Spyridon K Kritas; Gianpaolo Ronconi; Alessandro Caraffa; Theoharis C Theoharides
Journal:  Immunol Res       Date:  2017-10       Impact factor: 2.829

3.  IL32 is progressively expressed in mycosis fungoides independent of helper T-cell 2 and helper T-cell 9 polarization.

Authors:  Hanako Ohmatsu; Daniel Humme; Nicholas Gulati; Juana Gonzalez; Markus Möbs; Mayte Suárez-Fariñas; Irma Cardinale; Hiroshi Mitsui; Emma Guttman-Yassky; Wolfram Sterry; James G Krueger
Journal:  Cancer Immunol Res       Date:  2014-06-17       Impact factor: 11.151

4.  The role of IL-32 in cutaneous T-cell lymphoma.

Authors:  Hiraku Suga; Makoto Sugaya; Tomomitsu Miyagaki; Makiko Kawaguchi; Hideki Fujita; Yoshihide Asano; Yayoi Tada; Takafumi Kadono; Shinichi Sato
Journal:  J Invest Dermatol       Date:  2013-11-13       Impact factor: 8.551

5.  TLR3/TRIF signalling pathway regulates IL-32 and IFN-β secretion through activation of RIP-1 and TRAF in the human cornea.

Authors:  Ga Bin Park; Dae Young Hur; Yeong Seok Kim; Hyun-Kyung Lee; Jae Wook Yang; Daejin Kim
Journal:  J Cell Mol Med       Date:  2015-03-06       Impact factor: 5.310

6.  IL-32γ promotes the healing of murine cutaneous lesions caused by Leishmania braziliensis infection in contrast to Leishmania amazonensis.

Authors:  Rodrigo Saar Gomes; Muriel Vilela Teodoro Silva; Jéssica Cristina Dos Santos; Lucas Luiz de Lima Silva; Aline Carvalho Batista; Juliana Reis Machado; Mauro Martins Teixeira; Miriam Leandro Dorta; Milton Adriano Pelli de Oliveira; Charles A Dinarello; Leo A B Joosten; Fátima Ribeiro-Dias
Journal:  Parasit Vectors       Date:  2017-07-14       Impact factor: 3.876

7.  IL-32 gamma reduces lung tumor development through upregulation of TIMP-3 overexpression and hypomethylation.

Authors:  Jaesuk Yun; Mi Hee Park; Dong Ju Son; Kyung Tak Nam; Dae Bong Moon; Jung Heun Ju; Ok Kyung Hwang; Jeong Soon Choi; Tae Hoon Kim; Young Suk Jung; Dae Yeon Hwang; Sang Bae Han; Do-Young Yoon; Jin Tae Hong
Journal:  Cell Death Dis       Date:  2018-02-21       Impact factor: 8.469

8.  Elevated Gene Expression of Interleukin-32 Isoforms Alpha, Beta, Gamma, and Delta in the Peripheral Blood of Chronic Psoriatic Patients.

Authors:  Hani A Al-Shobaili; Zafar Rasheed
Journal:  Diseases       Date:  2018-03-14

9.  Interleukin-32-induced thymic stromal lymphopoietin plays a critical role in macrophage differentiation through the activation of caspase-1 in vitro.

Authors:  Hyun-Ja Jeong; Sun-Young Nam; Hyun-A Oh; Na-Ra Han; Young-Sick Kim; Phil-Dong Moon; Seung-Youp Shin; Min-Ho Kim; Hyung-Min Kim
Journal:  Arthritis Res Ther       Date:  2012-11-28       Impact factor: 5.156

10.  Functional role of human interleukin-32 and nuclear transcription factor-kB in patients with psoriasis and psoriatic arthritis.

Authors:  Hani A Al-Shobaili; Jalees Farhan; Uzma Zafar; Zafar Rasheed
Journal:  Int J Health Sci (Qassim)       Date:  2018 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.